HealthBlawg

David Harlow's Health Care Law Blog

    • Twitter
    • Facebook
    • LinkedIn
    • RSS
    • Email
  • About
  • Archives
  • Podcast
  • Press
  • Awards/Reviews
  • HIPAA
  • HCSM

N of 1 – Reflections on Extracting Knowledge from Data

May 18, 2015

I was privileged to participate in last week’s Quantified Self Public Health symposium, where one of the threads of conversation focused on teasing strategies for generalizable improvements in health status out of the data collected by quantified selfers. Over time, there has existed significant tension between the prevalent use of the randomized clinical trial as the gold standard for medical research and the value of N of 1 studies, the measurement and examination of cause and effect in a population of one.

Clearly, “N of 1” studies have been responsible for numerous triumphs over time, and should not be kicked to the curb. AHRQ even published an N-of-1 Trials User’s Guide last year.

As an example of the limitations of the more broadly accepted clinical trial model that is required as a precondition for marketing pharmaceuticals in the US, a recent piece in Nature highlighted the fact that not everyone with the same medical condition responds well to a single indicated drug therapy. (This article was shared via the Twitter backchannel at QSPH.) The piece calls out the “top ten” drugs — the highest grossing drugs — as poster children for imprecision medicine. For each person they help, they fail to improve the conditions of between 3 and 24 people. (That means that for each person they help, between 3 and 24 people have been prescribed the drug, have taken it for at least a while, and have not experienced the clinical effect for which the drug was prescribed — all at the expense of significant wasted resources at the societal, business and individual levels.)

Not surprisingly, there is significant overlap between these top ten and the top ten by claim count and by cost in the data set recently released by CMS about Medicare Part D prescription drug plan spending in 2013. (Abilify, Advair, Crestor, Cymbalta ….)

While there is certainly still value in the randomized clinical trial (and many tools just over the horizon that will make them easier to perform), there is enormous untapped potential in the N-of-1 trial. Perhaps in the future an individual profile may be run against a prescription drug in a simulator as a matter of course, so that we can know in advance whether a particular drug will work for a particular patient. Here’s hoping that AHRQ’s framework for N-of-1 trials, taken together with the tools being used and developed in the QS community, lead to broader use of this tool in appropriate settings so that our collective health may be advanced with greater precision, one patient at a time.

David Harlow
The Harlow Group LLC
Health Care Law and Consulting

Photo credit: Joe via Flickr CC

Filed Under: FDA, Health care policy, Health Insurance, Health Law, Quantified Self

you might also like:

  1. 2015 Health IT Predictions and Reflections

  2. CVS and Google Health: adding lots of prescription data to PHRs

  3. Consumer Generated Data: Your "Data Exhaust"

« An avalanche of unnecessary medical care
Outsourced Chronic Care Management Services Can Help Physicians and Patients »

Trackbacks

  1. Medicare Part D payments: A little more sunshine – HealthBlawg says:
    May 19, 2015 at 9:21 am

    […] 05/18/2015: See more recent post, N of 1 – Reflections on Extracting Knowledge from Data, for one of the key limitations of these […]

Follow me on Twitter

David Harlow 💉😷 Follow 42,910 17,570

Mastodon @healthblawg@c.im #HealthCare #MedDevice #Compliance #Privacy @MyOmnipod #HIPAA #digitalhealth #HarlowOnHC #pinksocks Tweets are tweets No more no less

healthblawg
healthblawg avatar; David Harlow 💉😷 @healthblawg ·
5h 1620535759902998528

The Harlow #Healthcare #Innovation Daily #digitalhealth #hcldr #HarlowOnHC #digitalhealth #healthtech

Image for twitter card

Google Research and DeepMind develop AI medical chatbot

digitalhealth.net A new AI-powered medical-specific chatbot developed by Google and DeepMind has shown some potential for clinical applications.

paper.li

Reply on Twitter 1620535759902998528 Retweet on Twitter 1620535759902998528 0 Like on Twitter 1620535759902998528 0 Twitter 1620535759902998528
healthblawg avatar; David Harlow 💉😷 @healthblawg ·
6h 1620524933863378944

ICYMI> Paul Schrimpf, at Prophet Consulting, Driving Health Care Transformation — Harlow on Healthcare https://healthblawg.com/2022/12/paul-schrimpf-prophet-consulting.html?utm_source=twitter&utm_medium=social&utm_campaign=ReviveOldPost #digitalhealth #hcldr #hitsm

Image for the Tweet beginning: ICYMI>  Paul Schrimpf, at Twitter feed image.
Reply on Twitter 1620524933863378944 Retweet on Twitter 1620524933863378944 0 Like on Twitter 1620524933863378944 0 Twitter 1620524933863378944
healthblawg avatar; David Harlow 💉😷 @healthblawg ·
11h 1620445622955278337

Moonshots — StartUp Health https://paper.li/healthblawg/1369855999?read=https%3A%2F%2Fwww.startuphealth.com%2Fmoonshots #hcldr

Reply on Twitter 1620445622955278337 Retweet on Twitter 1620445622955278337 0 Like on Twitter 1620445622955278337 0 Twitter 1620445622955278337
Load More
Follow me on Mastodon

HIPAAtools

Hipaatools

The HIPAA Compliance Toolkit

The Walking Gallery

The Walking Gallery

Quick Links

  • Home
  • Categories
  • Archives
  • Podcast Interviews
  • HIPAAtools
  • HIPAA Compliance
  • Health Care Social Media
  • Speaking
  • In the Press
  • Blogroll

David Harlow

David Harlow

HealthcareNOW Radio

Connect with David

  • Twitter
  • Facebook
  • LinkedIn
  • RSS
  • Email
  • Subscribe
  • Contact
  • Book Me: Speaking
  • About
  • The Harlow Group LLC
Copyright © 2006–2023
HealthBlawg is a publication of The Harlow Group LLC. See Copyright notice and disclaimer.
Fair use with attribution and a link is encouraged. Click for more on David Harlow.
[footer_backtotop text="Back to top" href="#"]